Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment

Cancer Res. 2002 May 15;62(10):2758-60.

Abstract

Systemic cisplatin-based chemotherapy cures > or =90% of patients with metastatic germ cell tumors (GCTs). The biological basis of this exquisite chemo-sensitivity and the resistant phenotype encountered in 10-15% of patients with GCT is yet unclear. A defective mismatch repair pathway leading to microsatellite instability (MSI) has been related to resistance to cytotoxic drugs. We investigated 100 unselected GCTs and 11 clinically defined chemotherapy-resistant GCTs for MSI using 8 mono- or dinucleotide markers and the presence of the mismatch repair factors MLH1, MSH2, and MSH6 by immunohistochemistry. The resistant tumors, both chemo-naïve (n = 8) and pretreated (n = 3), showed a significantly higher incidence of MSI compared with the unselected series (45 versus 6% in at least one locus and 36 versus 0% in > or =2 of 8 loci, both P < or = 0.001). In 5 of all 11 unstable tumors, MSI correlated with immunohistochemical findings. This study demonstrates for the first time a positive correlation between MSI and treatment resistance in GCT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carrier Proteins
  • Cisplatin / administration & dosage
  • DNA, Neoplasm / genetics*
  • DNA-Binding Proteins / metabolism
  • Disease-Free Survival
  • Drug Resistance, Neoplasm
  • Germinoma / drug therapy*
  • Germinoma / genetics*
  • Germinoma / metabolism
  • Humans
  • Immunohistochemistry
  • Male
  • Microsatellite Repeats / genetics*
  • Middle Aged
  • MutL Protein Homolog 1
  • MutS Homolog 2 Protein
  • Neoplasm Proteins / metabolism
  • Nuclear Proteins
  • Proto-Oncogene Proteins / metabolism
  • Seminoma / drug therapy
  • Seminoma / genetics
  • Seminoma / metabolism
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / genetics*
  • Testicular Neoplasms / metabolism

Substances

  • Adaptor Proteins, Signal Transducing
  • Carrier Proteins
  • DNA, Neoplasm
  • DNA-Binding Proteins
  • G-T mismatch-binding protein
  • MLH1 protein, human
  • Neoplasm Proteins
  • Nuclear Proteins
  • Proto-Oncogene Proteins
  • MSH2 protein, human
  • MutL Protein Homolog 1
  • MutS Homolog 2 Protein
  • Cisplatin